Abstract
The in vitro activity of AZD2563, a novel oxazolidinone, was assessed against 595 Gram-positive cocci, comprising recent surveillance isolates and a collection of resistant (including multiresistant), epidemiologically diverse isolates. The MICs of AZD2563 for staphylococci, pneumococci and enterococci had narrow ranges, 0.25-2 mg/L, with modal MICs of 1 mg/L for staphylococci and pneumococci, and 1-2 mg/L for enterococci. AZD2563 was equally active against the surveillance isolates and those that had been selected for their multiresistance to other agents. The MICs of AZD2563 were either the same as those of linezolid or two-fold lower.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acetamides / pharmacology
-
Anti-Bacterial Agents / pharmacology*
-
Coagulase / metabolism
-
Drug Resistance, Multiple, Bacterial*
-
Enterococcus faecalis / drug effects
-
Enterococcus faecalis / isolation & purification
-
Enterococcus faecium / drug effects
-
Enterococcus faecium / isolation & purification
-
Gram-Positive Cocci / drug effects*
-
Gram-Positive Cocci / isolation & purification
-
Humans
-
Linezolid
-
Microbial Sensitivity Tests
-
Oxazolidinones / pharmacology*
-
Staphylococcus aureus / drug effects
-
Staphylococcus aureus / enzymology
-
Staphylococcus aureus / isolation & purification
-
Streptococcus pneumoniae / drug effects
-
Streptococcus pneumoniae / isolation & purification
Substances
-
Acetamides
-
Anti-Bacterial Agents
-
Coagulase
-
Oxazolidinones
-
posizolid
-
Linezolid